257 related articles for article (PubMed ID: 32185726)
1. Therapeutic Development of Immune Checkpoint Inhibitors.
Wang J; Yang T; Xu J
Adv Exp Med Biol; 2020; 1248():619-649. PubMed ID: 32185726
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Resistance to Checkpoint Blockade Therapy.
Shi H; Lan J; Yang J
Adv Exp Med Biol; 2020; 1248():83-117. PubMed ID: 32185708
[TBL] [Abstract][Full Text] [Related]
4. Discovery of New Immune Checkpoints: Family Grows Up.
Kong X
Adv Exp Med Biol; 2020; 1248():61-82. PubMed ID: 32185707
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors.
Haanen JB; Robert C
Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
[TBL] [Abstract][Full Text] [Related]
6. Not All Immune Checkpoints Are Created Equal.
De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2018; 9():1909. PubMed ID: 30233564
[TBL] [Abstract][Full Text] [Related]
7. Programmed death 1 immune checkpoint inhibitors.
Trivedi MS; Hoffner B; Winkelmann JL; Abbott ME; Hamid O; Carvajal RD
Clin Adv Hematol Oncol; 2015 Dec; 13(12):858-68. PubMed ID: 27058852
[TBL] [Abstract][Full Text] [Related]
8. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation: A Fast Switch For Checkpoint Signaling.
Wang Y; Wang P; Xu J
Adv Exp Med Biol; 2020; 1248():347-398. PubMed ID: 32185718
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S
Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847
[TBL] [Abstract][Full Text] [Related]
11. Genetic Alterations and Checkpoint Expression: Mechanisms and Models for Drug Discovery.
Ding S; Li S; Zhang S; Li Y
Adv Exp Med Biol; 2020; 1248():227-250. PubMed ID: 32185713
[TBL] [Abstract][Full Text] [Related]
12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
13. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
Hailemichael Y; Woods A; Fu T; He Q; Nielsen MC; Hasan F; Roszik J; Xiao Z; Vianden C; Khong H; Singh M; Sharma M; Faak F; Moore D; Dai Z; Anthony SM; Schluns KS; Sharma P; Engelhard VH; Overwijk WW
J Clin Invest; 2018 Apr; 128(4):1338-1354. PubMed ID: 29480817
[TBL] [Abstract][Full Text] [Related]
14. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
15. Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects.
Long L; Zhao C; Ozarina M; Zhao X; Yang J; Chen H
Clin Drug Investig; 2019 Apr; 39(4):341-353. PubMed ID: 30778885
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations.
Baksh K; Weber J
Semin Oncol; 2015 Jun; 42(3):363-77. PubMed ID: 25965355
[TBL] [Abstract][Full Text] [Related]
17. Introduction.
Liu J; Xu J
Adv Exp Med Biol; 2020; 1248():1-6. PubMed ID: 32185704
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications.
Krueger J; Rudd CE; Taylor A
Semin Immunol; 2019 Apr; 42():101295. PubMed ID: 31604533
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors for cancer treatment.
Park J; Kwon M; Shin EC
Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]